Stock 300149 CHEMPARTNER PHARMATECH CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Chempartner Pharmatech Co., Ltd.

Equities

300149

CNE100000Y27

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
5.27 CNY +1.74% Intraday chart for Chempartner Pharmatech Co., Ltd. +19.23% -31.11%
Apr. 25 Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 25 Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 7,312 6,627 7,362 6,882 5,184 3,809
Enterprise Value (EV) 1 7,661 7,216 8,268 8,449 5,388 4,095
P/E ratio 41.8 x 47.7 x 47.6 x -17 x 13.7 x -4.2 x
Yield 0.48% - 0.48% - - -
Capitalization / Revenue 7.33 x 4.99 x 4.97 x 4.07 x 3.91 x 3.35 x
EV / Revenue 7.68 x 5.43 x 5.58 x 5 x 4.06 x 3.6 x
EV / EBITDA 30.9 x 25.5 x 27.1 x 48.3 x 572 x 203 x
EV / FCF -362 x 40.7 x -19.8 x 112 x -28.3 x -120 x
FCF Yield -0.28% 2.46% -5.04% 0.89% -3.53% -0.84%
Price to Book 3.34 x 2.89 x 3.03 x 3.5 x 2.2 x 2.62 x
Nbr of stocks (in thousands) 499,777 499,777 499,777 498,327 497,964 497,964
Reference price 2 14.63 13.26 14.73 13.81 10.41 7.650
Announcement Date 4/11/19 4/23/20 4/27/21 4/29/22 4/26/23 4/25/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 996.9 1,328 1,482 1,691 1,327 1,138
EBITDA 1 248.2 282.6 305.2 175 9.422 20.22
EBIT 1 184 183.7 201.6 65.31 -95.56 -50.69
Operating Margin 18.46% 13.84% 13.61% 3.86% -7.2% -4.45%
Earnings before Tax (EBT) 1 178.2 144 193.5 -361 744.7 -931
Net income 1 161.1 138.9 154.6 -402.2 378.6 -907.9
Net margin 16.16% 10.46% 10.43% -23.79% 28.54% -79.76%
EPS 2 0.3500 0.2780 0.3092 -0.8100 0.7600 -1.820
Free Cash Flow 1 -21.14 177.4 -416.7 75.59 -190.4 -34.24
FCF margin -2.12% 13.36% -28.12% 4.47% -14.35% -3.01%
FCF Conversion (EBITDA) - 62.78% - 43.19% - -
FCF Conversion (Net income) - 127.7% - - - -
Dividend per Share 2 0.0700 - 0.0700 - - -
Announcement Date 4/11/19 4/23/20 4/27/21 4/29/22 4/26/23 4/25/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 349 589 906 1,568 205 286
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.405 x 2.084 x 2.968 x 8.956 x 21.71 x 14.14 x
Free Cash Flow 1 -21.1 177 -417 75.6 -190 -34.2
ROE (net income / shareholders' equity) 10.5% 6.03% 6.48% -18.1% 17.3% -46.9%
ROA (Net income/ Total Assets) 5.24% 3.23% 3.19% 0.98% -1.49% -1.01%
Assets 1 3,074 4,304 4,838 -41,092 -25,487 90,047
Book Value Per Share 2 4.380 4.590 4.860 3.940 4.740 2.920
Cash Flow per Share 2 0.3800 0.4000 0.5200 0.3200 1.530 0.6900
Capex 1 110 254 394 286 336 201
Capex / Sales 11.02% 19.15% 26.6% 16.92% 25.34% 17.68%
Announcement Date 4/11/19 4/23/20 4/27/21 4/29/22 4/26/23 4/25/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CHEMPARTNER PHARMATECH CO., LTD. Stock Chempartner Pharmatech Co., Ltd.
-31.11% 363M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.17% 42.19B
MODERNA, INC. Stock Moderna, Inc.
+10.92% 42.24B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 40.15B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.23% 24.63B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.79% 18.2B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.69% 12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.13% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.57% 10.4B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 300149 Stock
  4. Financials Chempartner Pharmatech Co., Ltd.